| Assessment Status | Rapid Review Complete |
| Drug | Sufentanil Citrate |
| Brand | Dzuveo® |
| Indication | For the management of acute moderate to severe pain in adult patients |
| Assessment Process | |
| Rapid review commissioned | 02/10/2023 |
| Rapid review resubmission required | 04/12/2023 |
| Rapid review completed | 22/12/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that sufentanil citrate not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in
the Health (Pricing and Supply of Medical Goods) Act 2013.